Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
Zacks Investment Research on MSN
Novo Nordisk vs. Amgen: Which healthcare stock is the smarter choice?
Both Novo Nordisk NVO and Amgen AMGN are large-cap, innovation-driven healthcare leaders with global scale, strong balance ...
Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...
SEOUL, Dec. 23 (Yonhap) -- Samsung Bioepis Co., a biosimilar drug developer under Samsung Group, said Tuesday it has received ...
Samsung Bioepis Co., Ltd. today announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes ...
Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ stock is a Buy.
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeymatm, a ...
Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO' has been granted marketing approval in Japan First marketing approval under the partnership with NIPRO CORPORATION, paving the way ...
Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback